Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Nefrología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)
INTERVENTIONAL
Inicio: 1 de feb de 2016
ID: NCT02680574
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 23 de jul de 2017
ID: NCT03141177
Completado
Fase 2
ClinicalTrials.gov
A Partially Blinded, Prospective, Randomized Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral Sotrastaurin Plus Standard or Reduced Exposure Tacrolimus vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients
INTERVENTIONAL
Inicio: 1 de dic de 2009
ID: NCT01064791
Reclutando
Fase 3
ClinicalTrials.gov
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
INTERVENTIONAL
Inicio: 8 de nov de 2022
ID: NCT05457283
Reclutando
ClinicalTrials.gov
Prospective Urban Rural Epidemiology Study
OBSERVATIONAL
Inicio: 1 de ene de 2002
ID: NCT03225586
Completado
Fase 3
ClinicalTrials.gov
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00474786
Completado
Fase 2
ClinicalTrials.gov
A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
INTERVENTIONAL
Inicio: 17 de sept de 2021
ID: NCT05027074
Reclutando
Fase 3
ClinicalTrials.gov
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
INTERVENTIONAL
Inicio: 21 de jul de 2021
ID: NCT04877288
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
INTERVENTIONAL
Inicio: 26 de nov de 2025
ID: NCT07227402
Activo, no recluta
ClinicalTrials.gov
FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting
OBSERVATIONAL
Inicio: 13 de jun de 2022
ID: NCT05348733
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)
INTERVENTIONAL
Inicio: 11 de dic de 2025
ID: NCT07144163
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
INTERVENTIONAL
Inicio: 29 de mar de 2024
ID: NCT06268873
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
INTERVENTIONAL
Inicio: 10 de abr de 2024
ID: NCT06307431
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01491672
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus Versus Cyclosporine When Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients
INTERVENTIONAL
Inicio: 1 de jun de 2005
ID: NCT00137345
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy
INTERVENTIONAL
Inicio: 1 de dic de 2012
ID: NCT01712061
Activo, no recluta
Fase 3
ClinicalTrials.gov
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
INTERVENTIONAL
Inicio: 6 de abr de 2023
ID: NCT05746559
Activo, no recluta
Fase 3
ClinicalTrials.gov
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
INTERVENTIONAL
Inicio: 9 de sept de 2021
ID: NCT04987203
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 16 de ene de 2014
ID: NCT01989754
Completado
Fase 3
ClinicalTrials.gov
An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00387764
Anterior
1
...
11
12
13
...
434
Siguiente
Filtros